ABSTRACT: Calcium (Ca 2+ ) is a physiological key factor, and the precise modulation of free cytosolic Ca 2+ levels regulates multiple cellular functions. Store-operated Ca 2+ entry (SOCE) is a major mechanism controlling Ca 2+ homeostasis, and is mediated by the concerted activity of the Ca 2+ sensor STIM1 and the Ca 2+ channel ORAI1. Dominant gain-of-function mutations in STIM1 or ORAI1 cause tubular aggregate myopathy (TAM) or Stormorken syndrome, whereas recessive loss-of-function mutations are associated with immunodeficiency. Here, we report the identification and functional characterization of novel ORAI1 mutations in TAM patients. We assess basal activity and SOCE of the mutant ORAI1 channels, and we demonstrate that the G98S and V107M mutations generate constitutively permeable ORAI1 channels, whereas T184M alters the channel permeability only in the presence of STIM1. These data indicate a mutationdependent pathomechanism and a genotype/phenotype Additional Supporting Information may be found in the online version of this article. 
Introduction
Skeletal muscle physiology directly depends on changes in free cytosolic calcium (Ca 2+ ) levels, and small disturbances in Ca 2+ homeostasis can severely impact on muscle contraction, differentiation, or gene transcription. A major mechanism controlling Ca 2+ homeostasis is store-operated Ca 2+ entry (SOCE), which is triggered by Ca 2+ store depletion of the endoplasmic/sarcoplasmic reticulum (ER/SR), and results in extracellular Ca 2+ influx through Ca 2+ release-activated Ca 2+ (CRAC) channels as ORAI1 (MIM# 610277). This highly Ca 2+ -selective plasma membrane (PM) channel is composed of tetramers or hexamers forming three concentric rings around the central pore [Hou et al., 2012; Thompson and Shuttleworth 2013; Cai et al., 2016] . Each ORAI1 subunit is composed of four alpha-helical transmembrane domains (M1-M4) linked by two external (I and III) and one internal (II) loop, with the N-and C-termini facing the cytosol. The M1 transmembrane domain constitutes the ß55Å long channel pore with an acidic glutamate ring at position E106 forming the selectivity filter and, together with negative residues in the first external loop, conferring high selectivity for Ca 2+ ions [Vig et al., 2006; Zhou et al., 2010; McNally et al., 2012; Frischauf et al., 2015] . The central segment of the pore contains a rigid hydrophobic section responsible for the low channel conductance, a gating hinge controlling pore opening, and a basal component potentially avoiding backward Ca 2+ efflux from the cytoplasm [Zhang et al., 2011] .
Channel opening is mediated through the interaction of the cytoplasmic N-and C-termini of the ORAI1 subunits with STIM1 (MIM# 605921), a transmembrane protein in the ER/SR able to sense luminal Ca 2+ [Muik et al., 2008; Navarro-Borelly et al., 2008; Zheng et al., 2013] . Ca 2+ store depletion induces a conformational change resulting in oligomerization and cytosolic extension of the STIM1 molecules. The exposure of lipid-binding and channel activating domains promotes the accumulation of the STIM1 oligomers at junctional ER/SR structures near the PM, where they trap and gate the ORAI1 channels [Luik et al., 2006; Stathopulos et al., 2006; Park et al., 2009] .
We previously identified STIM1 gain-of-function mutations as genetic cause of autosomal dominant tubular aggregate myopathy (TAM; MIM# 160565) [Bohm et al., 2013] . TAM mostly involves elevated creatine kinase (CK) levels and slowly progressive muscle weakness predominantly affecting the proximal muscles of the lower limbs, but also myalgia, cramps, and asymptomatic CK elevation have been described [Bohm et al., 2013; Bohm et al., 2014; Hedberg et al., 2014; Walter et al., 2015] . Muscle biopsies from patients with TAM typically show regular arrays of 70-200 nm long membrane tubules as the main histopathological hallmark [Chevessier et al., 2005] . Tubular aggregates can also arise as secondary features in various inherited and acquired muscle disorders, and accumulate in normal muscle with age [Boncompagni et al., 2012] . All TAM mutations affect highly conserved amino acids in the Ca 2+ -sensing EF hand domains of STIM1. The only cytosolic STIM1 mutation R304W has been associated with Stormorken syndrome (MIM# 185070), a multisystemic disorder involving tubular aggregate myopathy, miosis, thrombocytopenia, ichthyosis, asplenia, dyslexia, and short stature [Misceo et al., 2014; Morin et al., 2014; Nesin et al., 2014] . Mutations in STIM1 causing either TAM or Stormorken syndrome were both shown to induce constitutive STIM1 oligomerization, CRAC channel activation and Ca 2+ influx in the absence of store depletion [Bohm et al., 2013; Bohm et al., 2014; Misceo et al., 2014; Nesin et al., 2014] . Recently, three gain-offunction mutations causing TAM or a Stormorken-like syndrome were also described in ORAI1 [Nesin et al., 2014; Endo et al., 2015] . These mutations did not alter ORAI1 localization at the PM, but resulted in increased SOCE and diminished Ca 2+ -dependent channel inactivation (CDI).
This study reports the identification of three ORAI1 gain-offunction mutations (two in the channel pore and one in M3) in patients with TAM with or without isolated characteristics of Stormorken syndrome. Based on clinical, histological, genetic, and functional data, we establish a genotype/phenotype correlation and conclude that TAM and Stormorken syndrome clinically overlap, and have to be considered as spectra of the same disease. We provide the functional evidence that mutations in the first transmembrane domain induce a STIM1-independent permeable Ca 2+ channel resulting in a more severe phenotype, whereas the mutation in the third transmembrane domain requires activation through STIM1 to generate an excessive Ca 2+ influx and causes a milder phenotype, suggesting that the ORAI1 mutations involve different pathological mechanisms.
Materials and Methods

Patients
Sample collection was performed with informed consent from the patients according to the declaration of Helsinki and experimentation was performed following institutional IRB-accepted protocols and the Comité de Protection des Personnes Est IV (DC-2012 (DC- -1693 . Patients were from Honduras (Family 1), the United Kingdom (Family 2), and Italy (Family 3).
Sequencing and Segregation Analysis
Genomic DNA was prepared from peripheral blood by routine procedures and STIM1 mutations were excluded by Sanger sequencing. Whole exome sequencing was carried out for patient 11200 from Family 1, and for patients II.1, II.3, and IV.1 from Family 2 using the SureSelect Human All Exon Kit v4 (Agilent, Santa Clara, CA) and the Illumina HiSeq 2000 or 2500 systems (Illumina, San Diego, CA). Sequence data were aligned to the GRCh37/hg19 reference genome using the BurrowsWheeler aligner software (http://bio-bwa.sourceforge.net), and variant calling was performed with SAMtools [Li et al., 2009] or the UnifiedGenotyper (https://www.broadinstitute.org/gatk). Following databases were used for SNP annotation and filtering: Exome Variant Server (http://evs.gs.washington.edu/EVS/), ExAC Browser (http://exac.broadinstitute.org/), dbSNP (http://www. ncbi.nlm.nih.gov/projects/SNP/), 1000 genomes (http://www. 1000genomes.org/), as well as the in-house exome databases in Illkirch and Manchester. Impacts of variations were predicted using Alamut v.2.5 (http://www.interactive-biosoftware.com).
For patient 5510 from Family 3, direct Sanger-sequenced for both coding exons of ORAI1 and the adjacent splice-relevant regions was performed. Segregation analyses for Families 1 and 2 were also performed by Sanger sequencing. The ORAI1 mutations were numbered according to GenBank NM 032790.3 and NP 116179.2. Nucleotide position reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon. All identified mutations have been submitted to the LOVD database (http://www.lovd.nl/ORAI1).
Histology and Electron Microscopy
For histology, transverse sections (10 μm) of the muscle biopsies were stained with modified Gomori Trichrome, NADH tetrazolium reductase (NADH-TR) and succinic dehydrogenase (SDH) and assessed for fiber morphology, fiber type distribution, and accumulations/infiltrations.
For electron microscopy, muscle sections were fixed in 2.5% paraformaldehyde, 2.5% glutaraldehyde, and 50 mM CaCl 2 in 0.1 M cacodylate buffer (pH 7.4). Samples were postfixed with 2% OsO 4 , 0.8% K 3 Fe(CN) 6 in 0.1 M cacodylate buffer (pH 7.4) for 2 hr at 4°C and incubated with 5% uranyl acetate for 2 hr at 4°C. Muscles were dehydrated in a graded series of ethanol and embedded in epon resin. Thin sections were examined with an electron microscope (Philips CM120, FEI Company, Hillsboro, OR).
Protein Studies
Immunofluorescence was performed with routine protocols using following antibodies: rabbit anti-Orai1 (Abcam, Paris, France), HUMAN MUTATION, Vol. 38, No. 4, 426-438, 2017 mouse anti-GOK/Stim1 (BD Biosciences, Franklin Lakes, NJ), mouse Anti-Ryanodine receptor Clone 34C Product R-12 (SigmaAldrich, Saint Louis, MO), NCL-SERCA2 mouse monoclonal antibody, clone IID8 (Novocastra, Newcastle, UK). Sections were mounted with antifade reagent (Invitrogen, Carlsbad, CA) and viewed using a laser scanning confocal microscope (TCS SP2; Leica Microsystems, Wetzlar, Germany).
Constructs
The human ORAI-eGFP and mCherry-STIM1 constructs were kind gifts from Liangyi Chen (Beijing University, China) and Richard S. Lewis (Stanford University). The ORAI1 point mutations (c.292G>A, c.319G>A, c.551C>T) were introduced by site-directed mutagenesis using the Pfu DNA polymerase (Stratagene, La Jolla, CA). The plasmid carrying an untagged STIM1 was purchased from OriGene (NM 003156; OriGene Technologies, Rockville, MD), and the control vector pEGFP-C1 from Clontech (Palo Alto, CA).
Cells and Transfections
Stim1
-/-/Stim2 -/-mouse embryonic fibroblasts (MEF-DKO), generated by targeted gene disruption, were a kind gift from Masatsugu Oh-Hora (Tokyo Medical and Dental University, Japan), and HEK-293T cells were purchased from ATCC (CRL-11268; Manassas, VA). MEF-DKO and HEK-293T cells were respectively cultured in DMEM 15140-122 and 31966-021 (Gibco Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (10270-106; Gibco Life Technologies), 5 μg/ml streptomycin and 5 units/ml penicillin (15140-122; Gibco Life Technologies), and were maintained at 37°C in 5% CO 2 . Cells were seeded on poly-L-lysine (P4832; Sigma-Aldrich) coated glass coverslips, and transfected at 50% confluency with Lipofectamine R 2000 (11668-019; Invitrogen). For co-expression experiments, mCherry-STIM1 and ORAI1-eGFP constructs were transfected in a 3:1 ratio by mass. For cells transfected with the ORAI1-eGFP G98S mutant and the respective controls, low Ca 2+ containing medium (0.2 mM CaCl 2 ) was used to prevent Ca 2+ toxicity. All subsequent experiments were performed within 24 hr post transfection.
Total Internal Reflection Fluorescence Microscopy
To assess the impact of the ORAI1 mutations on the channel distribution at the PM, HEK-293T cells were co-transfected with wild-type (WT) or mutated ORAI1-eGFP and an untagged STIM1 construct, and cultured overnight in low Ca 2+ containing medium complemented with 5 μM lanthanum. The total internal reflection fluorescence (TIRF) plane was determined according to the PM GFP fluorescence at resting state, and images were collected by a Nikon Eclipse Ti microscope (Tokyo, Japan) equipped with a Perfect Focus System, a 100×1.49 Oil CFI Apochromat TIRF objective and a cooling EMCCD iXon camera (DU-897E-CS0-#BV-500; Andor Technology Ltd., Belfast, Northern Ireland). Cells were excited with a 488 nm 50 mW laser and light was collected through the TIRF Quad dichroic beamsplitter 405/488/561/640 and the emission filter FITC 525/50 from Nikon. The experiment was performed at room temperature. Cells were treated with 1 μM Thapsigargin (Tg) (SigmaAldrich) to follow the kinetics of ORAI1 clustering at the PM. Live images were acquired with the NIS-Elements AR software V4.30.02 (Nikon), and ORAI1 clusters were quantified and characterized with a granularity detection journal on Metamorph software 7.8.12.0 (Molecular Devices, Sunnyvale, USA) after background subtraction. Regions containing clusters were identified at the end of each experiment and their increasing intensities were plotted over time. The results were normalized as follows:
is the fluorescence intensity of a cluster at a given time, Fcr (t = n) the intensity measured in a region that will contain a cluster following store depletion, and Frr (t = n) the intensity of a reference region devoid of clusters throughout the experiment. The average fluorescence intensity of cumulated clusters at the cellular level (F (t = n) ) was normalized to the fluorescence of the empty region at the beginning of the experiment (F 0 = Frr (t = 0) ). The percentage of the PM covered by clusters (density) was determined as the summed area of clusters divided by the total surface of the PM visible in the TIRF plane.
Ca
2+ Measurements
To assess cytosolic Ca 2+ levels, cells were loaded at room temperature with 4 μM of the Ca 2+ sensor Fura-2 AM and 1 μM Pluronic acid F-127 (F-1201 and P-3000MP; Invitrogen) in 2 or 0.2 mM CaCl 2 recording solution. After 30 min in the dark, cells were washed and allowed for de-esterification for at least 15 min. Fura-2 ratiometric fluorescence emission was recorded with an Axio Observer microscope (Zeiss, Jena, Germany) equipped with a Lambda DG4 175 watts xenon arc lamp (Sutter Instrument Company, Novato, CA) and a rapidly changing filter wheel (Ludl Electronic Products, München, Germany). Excitation filters 340AF15 and 380AF15 were purchased from Omega Optical (Brattleboro, VT). Exposure time was 500 msec every 3 sec for each wavelength. Emission was collected through the dichroic/filter couple 415DCLP/510WB40 (Omega Optical), by a 12-bit CCD cooling camera (CoolSnap HQ, Ropper Scientific, Trenton, NJ) with a 2× gain and a binning of 4. To measure SOCE, 1 μM Tg was used to passively deplete the Ca 2+ stores. For Mn 2+ quenching experiments, 500 μM Mn 2+ were added while cells were excited at 360 nm (360BP10; Omega Optical). Recording solutions contained 140 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 10 mM Hepes, 10 mM D-(+)-glucose and the indicated amounts of CaCl 2 . The Ca 2+ -free solution contained 1 mM EGTA instead of CaCl 2 . The pH was adjusted to 7.4 at 37°C with NaOH. All experiments were achieved at 37°C with pre-heated solutions. Ca 2+ recordings were acquired and analyzed with the Metafluor 6.3 software (Universal Imaging, West Chester, PA) after background subtraction. For cells co-expressing mCherry-STIM1 and ORAI1-eGFP constructs, only cells with a mCherry/eGFP fluorescence ratio above 1 were analyzed.
Statistics
GraphPad Prism 6.05 was used for statistical evaluation of the data. Statistical significance was determined by the two-tailed unpaired Student's t test with systematic Welch correction for variance.
Results
Clinical Reports
The patients characterized in this study belong to three unrelated families with a broad range of symptoms and signs with different ages of onset and disease severity, but sharing prominent tubular aggregates on muscle biopsies as the main histopathological hallmark. Patient 11200 (Family 1) is a singleton, Family 2 has an ancestral history of a muscle phenotype segregating as a dominant disease over at least four generations, and Family 3 displays a mother to son disease inheritance (clinical features summarized in Table 1 ).
Patient 11200 from Family 1 is now 12 years old. Pregnancy, birth, and neonatal history were uneventful, although motor milestones were slightly delayed. The patient achieved sitting at the age of 8 months, and independent walking at 24 months. Tip-toe-walking and frequent falls were noticed since age 2, and contractures of elbows and Achilles tendons were diagnosed in the following years. Clinical examination at the age of 10 revealed ichthyosis, stiffness, proximal muscle weakness, and reduced tendon reflexes of the lower limbs. The patient was unable to jump, and had a waddling gait. He reported cramps and myalgia, both at rest and after exercise, headaches, and frequent episodes of bleeding from mouth, nose, and bowel. He had anemia but not thrombocytopenia, and blood Ca 2+ levels were repeatedly normal or only mildly reduced. Eye examination showed miosis, heart and lung functions were normal, and cognitive assessment showed results within the normal range. CK levels were repeatedly elevated, with values up to 2,052 U/l. Motor nerve conduction velocities were normal and EMG showed chronic neurogenic abnormalities and mild myopathic changes in the proximal lower limbs. Muscle MRI revealed fibro-fatty replacements in the posterior and medial compartments of the thigh and of the posterior compartment of the calf (Supp. Fig. S1 ). Abdominal ultrasound excluded asplenia/hyposplenia. The parents and the younger sister are healthy.
For Family 2, five affected members underwent regular clinical examinations. They are now between 6 and 47 years old, and pregnancy, birth, and early childhood was normal for all. Slightly delayed motor milestones as well as slight dyslexia were reported for patients IV.1, and IV.2, and might have been overlooked for the older generations. All showed tip-toe walking associated to Achilles tendon contractures by the age of 8 years. Only the youngest patient, now 6 years old, does not show tip-toe walking. The proximal muscles of the lower limbs were predominantly affected, and involved weakness (II.1, III.1, III.2), stiffness (II.1, III.2), cramps (II.1, III.2), and myalgia (II.1, III.1, IV.1, IV.2). All had difficulties running and climbing stairs. Calf hypertrophy was noted for patients III.1 and IV.1. CK levels were elevated for all and ranged between 484 and 1,538 U/I. Motor nerve conduction velocity, assessed for patient III.1 was normal, and EMG showed myopathic changes.
Patient 5510 from Family 3 was diagnosed with asymptomatic hyperCKemia through routine blood tests at the age of 56. Medical examination at the age of 60 revealed mild general muscle weakness, and the patient reported myalgia of the lower limbs and cramps, but motor nerve conduction velocity and EMG did not reveal any abnormalities. The patient also presented with hypereosinophilia resulting from allergic diathesis, pectus excavatum, and arched palate. CK levels were repeatedly elevated and ranged between 400 and 600 U/I, and his mother was also reported to have asymptomatic hyperCKemia.
Histology and Ultrastructural Analyses Reveal Tubular Aggregates
Muscle biopsies from all patients described in this study displayed tubular aggregates appearing on Gomori trichrome and on NADH-TR staining (Fig. 1) . In agreement with previously described TAM cases, the aggregates are less detectable with SDH, suggesting a reticulum and not a mitochondrial origin [Chevessier et al., 2005; Bohm et al., 2013] . Aggregates were observed in both fiber types in all analyzed biopsies. Additional observations comprise fiber size variability and internalized nuclei.
Ultrastructural analyses demonstrated that the tubular aggregates are of variable size and consist of single or double-walled membranes of different diameter (Fig. 1) . Overall, the histological and ultrastructural features of the biopsies were strikingly similar and strongly suggestive of TAM.
Exome Sequencing Identifies Mutations in ORAII
Sanger sequencing of the known TAM gene STIM1 did not reveal any putative pathogenic variant in the families described here. We performed exome sequencing for Families 1 and 2, and identified heterozygous missense mutations in ORAI1. Patient 11200 from Family 1 carries the ORAI1 c.292G>A (p.Gly98Ser) de novo mutation in exon 1, and the affected members of Family 2 harbor the ORAI1 c.319G>A (p.Val107Met) mutation in exon 2 ( Fig. 2A) . Another missense mutation (c.551C>T; p.Thr184Met) in exon 2 was found by direct ORAI1 Sanger sequencing of patient 5510 from Family 3. None of the three mutations was found in the available healthy family members and none was listed in the public or internal SNP databases. However, the p.Gly98Ser mutation was previously described in an unrelated Japanese family with TAM involving diffuse muscle weakness, joint contractures, a rigid spine and hypocalcaemia [Endo et al., 2015] .
All three missense mutations affect highly conserved amino acids in ORAI1 (Fig. 2B) The mutations p.Gly98Ser and p.Val107Met affect amino acids in M1, and p.Thr184Met affects an amino acid in M3 (Fig. 2C) . M1 forms the ion conduction pathway, whereas M2 and M3 encircle the pore and are surrounded by the M4 outer ring [Hou et al., 2012; Frischauf et al., 2015] . The residue G98 is located in the rigid section of the channel responsible for ion conduction, and the residue V107 neighbors E106, involved in Ca 2+ selectivity.
Tubular Aggregates Contain STIM1
To characterize the structure and composition of the tubular aggregates associated with ORAI1 mutations, we performed immunolocalization experiments on muscle biopsies from patient 11200 (Family 1) and II.1 (Family 2) (Fig. 1) . We previously showed that tubular aggregates in TAM patients with STIM1 mutations contain various SR proteins as STIM1, the Ca 2+ channel RYR1 (MIM# 180901), the RYR1-effector triadin (MIM# 603283), or the Ca 2+ pump SERCA (MIM# 108730), and that RYR1 and STIM1 are exclusively found in the aggregate periphery [Bohm et al., 2013] . In agreement with our previous observations, the aggregates in the TAM patients with ORAI1 mutations also contain SERCA, and RYR1 is mainly found in the periphery of the aggregates (Fig. 1) . The aggregates display strong STIM1 signals, thereby linking STIM1 and ORAI1-related TAM. Of note, STIM1 signals are not restricted to the aggregate periphery; this is in contrast to the immunolocalization experiments in STIM1 patients, and might reflect different ways of tubular aggregate formation in patients with STIM1 or ORAI1 mutation. Aggregated ORAI1 is barely or not detectable on the biopsies of the analyzed patients, supporting the idea that tubular aggregates essentially consist of SR membrane and proteins.
ORAI1 Mutants Traffic Normally to PM Clusters
In order to assess the impact of the three ORAI1 mutations on channel localization and trafficking, we generated WT and ORAI1-eGFP G98S, V107M, and T184M constructs, exogenously co-expressed them with human STIM1 in HEK-293T cells, and imaged the formation of ORAI1 clusters at the PM by TIRF microscopy. WT and mutant ORAI1 were homogenously distributed in the TIRF plane in resting cells, and accumulated in clusters following depletion of ER Ca 2+ stores with the SERCA inhibitor Thapsigargin (Tg) (Fig. 3A) . The intensity of the clusters and the extent of cell membrane covered by clusters were comparable in cells expressing WT or mutant ORAI1 at resting or activated state ( Fig. 3B and C) . We therefore conclude that the mutations do not significantly alter the ORAI1 localization at the PM, nor ORAI1 clustering upon SOCE activation.
ORAI1 Mutations Produce Constitutively Active Channels
To evaluate the impact of the ORAI1 mutations on basal channel activity, we measured the cytosolic Ca 2+ levels ([Ca 2+ ] cyt ) in HEK-293T cells transfected with the ORAI1-eGFP constructs, and loaded with the ratiometric Ca 2+ sensor Fura-2, AM. Cells were sequentially exposed to Ca 2+ -rich and Ca 2+ -poor media to assess the extent of Ca 2+ entry across the channel in cells with replete stores (Fig. 4A-C) . Mean basal Fura-2 ratio values were elevated in cells expressing ORAI1 V107M (0.52, SD ± 0.14) or T184M (0.48, SD ± 0.10) compared with cells expressing WT ORAI1 (0.39, SD ± 0.08), and decreased significantly upon Ca 2+ removal. HEK-293T cells expressing the ORAI1 G98S construct displayed extremely high [Ca 2+ ] cyt in Ca 2+ -rich conditions and were cultured in 0.2 mM CaCl 2 to minimize cytotoxicity. Under these conditions, mean basal Fura-2 ratio was significantly elevated (0.68, SD ± 0.19, compared with WT 0.35, SD ± 0.03), decreased upon Ca 2+ removal, and markedly increased upon addition of 2 mM Ca 2+ (1.28, SD ± 0.20, compared with WT 0.36, SD ± 0.04, Fig. 4B and C) . These results HUMAN MUTATION, Vol. 38, No. 4, 426-438, 2017 Figure 2. Identification of ORAI1 mutations. A: Heterozygous ORAI1 missense mutations were identified in all three families, and segregated with the disease. B: The mutations affect highly conserved amino acids in ORAI1. C: Schematic representation of ORAI1. Mutations found in our patients are depicted in red, published mutations appear in blue. G98S and V107M affect amino acids in transmembrane domain 1 (M1), and T184M affects an amino acid in M3. Residue G98 is located in the rigid section of the channel, and V107 neighbors the Ca 2+ selectivity filter E106.
suggest that the mutated ORAI1 channels are Ca 2+ permeable even in the absence of store depletion, with a more pronounced degree of permeability for G98S compared to V107M or T184M ORAI1.
G98S and V107M Alter ORAI1 Activity Independently of STIM1
In order to assess the STIM-dependence of the constitutive activation of mutant ORAI1 channels, we next transfected mouse embryonic fibroblasts bearing a targeted disruption in the Stim1 and Stim2 genes (MEF-DKO). Since steady-state [Ca 2+ ] cyt reflects the combined activity of Ca 2+ pumps, channels, and exchangers, we used the Mn 2+ quench assay (Fig. 4D-F) . Mn 2+ permeates through Ca 2+ channels and quenches the Fura-2 fluorescence, thereby allowing the individual quantification of the influx component. In these experiments, we observed a massive Mn 2+ influx in MEF-DKO cells expressing ORAI1-eGFP V107M or G98S, whereas only a small Mn 2+ influx was detectable in cells expressing ORAI1-eGFP T184M or WT, with no significant difference among these two conditions. Similar results were obtained by measuring the amplitude of the Ca 2+ elevation evoked by the readmission of 2 mM Ca 2+ to MEF-DKO cells treated with Tg (Supp. Fig. S2 ), where Fura-2 ratio increase was observed only in cells expressing G98S or V107M ORAI1. In conclusion, G98S and V107, but not T184M ORAI1 channels appear constitutively active in the absence of STIM proteins. Accordingly, Mn 2+ quench experiments in HEK-293T cells endogenously expressing STIM1 and STIM2 demonstrated that cells transfected with any of the mutant channels including ORAI1-T184M displayed significant cation entry (Supp. Fig. S3 ).
The ORAI1 Mutants Mediate Excessive Ca 2+ Entry when Gated by STIM1
To test whether the ORAI1 mutations also impact on the STIM1-gated maximal channel activity, we co-transfected HEK-293T cells with mCherry-STIM1 and WT or mutated ORAI1-eGFP constructs. wild-type (WT) or mutated (V107M, T184M, G98S) ORAI1-eGFP taken before and 10 min after addition of 1 μM Thapsigargin (Tg). Insets show cluster morphology at higher magnification. B: Changes in intensity of eGFP clusters and in cluster density (% PM covered by clusters) in the TIRF plane following Tg addition in cells co-expressing STIM1 and WT or mutated ORAI1-eGFP. C: Statistical evaluation of eGFP cluster intensity and density before and after Tg treatment. Data are mean ± SEM of 33, 24, 25, and 14 cells for WT, V107M, T184M, and G98S, respectively. No statistically significant differences were observed between WT and mutated channels in resting and store-depleted conditions.
We induced passive reticular Ca 2+ depletion through Tg treatment in Ca 2+ -free medium, and measured SOCE upon readmission of 0.5 mM Ca 2+ to the medium. Cells expressing any of the ORAI1 mutants displayed significantly increased SOCE with 2-3-fold steeper slope of Fura-2 ratio increase compared with cells expressing WT ORAI1 (Fig. 5A and B) . Analysis of the response kinetics 60 sec after Ca 2+ admission demonstrated a 30% Fura-2 ratio decrease for cells transfected with WT or T184M ORAI1, whereas the ratio remained at near maximal levels in cells expressing G98S or V107M ORAI1 (Fig. 5C) .
To specifically assign ORAI1 channel activation to STIM1, we repeated the co-expression experiments in MEF-DKO cells (Fig. 5D-F) . Following Tg treatment and readmission of Ca 2+ , cells co-expressing STIM1 and V107M or T184M ORAI1 mutants displayed a strongly increased SOCE slope compared to cells coexpressing STIM1 and WT ORAI1. Expression of a control vector did not affect the Ca 2+ response of the recipient cells, and expression of STIM1 alone fully restored SOCE in the MEF-DKO cells (Supp. Fig. S2 ). Unexpectedly, MEF-DKO expressing STIM1 and WT or G98S ORAI1 and cultured in low Ca 2+ exhibited a high SOCE slope ( Fig. 5D and E) , potentially reflecting a specific adaptation of these cells to Ca 2+ deprivation, and resulting in a more efficient activation of the SOCE pathway. However, and in agreement with the results obtained in transfected HEK-293T cells, the Fura-2 ratio remained elevated 60 sec post Ca 2+ readmission in cells expressing the G98S and V107M mutants, whereas the ratio decreased in cells expressing T184M ORAI1 (Fig. 5F ).
Overall and in accordance with the Mn 2+ quenching data, these results strongly indicate a mutation-dependent pathomechanism. All three ORAI1 mutations G98S, V107M, and T184M involve maximal SOCE in presence of active STIM1, but only G98S and V107M generate a constant Ca 2+ influx independently of STIM1 activation. (D) and (E), measured between the time points indicated with # (n = 17, 20, 21 and 23, 32 for WT, V107M, T184M, and WT, G98S cultured in low Ca 2+ , respectively). Data are mean ± SEM, statistically significant differences versus respective WT conditions are indicated by * * * * P < 0.0001.
Discussion
Here, we report three ORAI1 mutations causing TAM, and we support our findings by clinical, histological, genetic, and functional data. Our patients presented with different age of onset, disease severity, and additional non-muscular features, suggesting that TAM and Stormorken syndrome are spectra of the same disease. We functionally demonstrate for the first time that the mutations in different ORAI1 transmembrane domains appear to involve different pathomechanisms, and thereby uncover a genotype-phenotype correlation. (F) . Statistically significant differences versus respective WT conditions are indicated by * * P < 0.01, * * * P < 0.001, and * * * * P < 0.0001.
Tubular Aggregates in ORAI1 Patients Contain STIM1
As both STIM1 and ORAI1 mutations lead to TAM, we compared the structure and composition of the tubular aggregates in our ORAI1 patients with the published STIM1 patients [Bohm et al., 2013] . The tubular aggregates in STIM1 patients were shown to contain diverse SR proteins as RYR1, triadin, SERCA, and STIM1, and STIM1 was mainly found in the periphery of the aggregates [Bohm et al., 2013] . Immunohistofluorescence on muscle sections from ORAI1 patients also demonstrated the presence of STIM1 and other SR proteins in the aggregates. This observation provides a link between STIM1 and ORAI1-related TAM at the histopathological level, and suggests that secondary STIM1 aggregation plays a role in the pathogenesis of ORAI1 mutations. Of note, the STIM1 signals were detectable in the periphery as well as in the center of the aggregates, potentially reflecting a difference in tubular aggregate formation in patients with STIM1 and ORAI1 mutation. Even if mutated, the PM Ca 2+ channel ORAI1 is barely or not detectable in the aggregates, confirming that the tubular aggregates are primarily of SR origin. Considering the increased Ca 2+ entry resulting from STIM1 or ORAI1 mutations, we might speculate that the excessive cellular Ca 2+ is in large parts stored in the reticulum, provoking reticular overload and dilatation, and resulting in cisternal pinching off to form the primary stage of the tubular aggregates. This is line with the observation that tubular aggregates contain large amounts of Ca 2+ [Salviati et al., 1985; Chevessier et al., 2005] .
ORAI1 Mutations Involve Different Pathomechanisms
To mechanistically investigate the impact of the ORAI1 G98S, V107M, and T184M mutations, we analyzed the channel activity in presence or absence of STIM1. Expression of any of the mutant ORAI1-eGFP constructs in HEK-293T cells resulted in elevated basal Ca 2+ levels, but in mouse fibroblasts devoid of STIM (Stim1 -/-/Stim2 -/-), only G98S and V107M induced significant cation influx in the Mn 2+ quench assay. This demonstrates that both G98S and V107M ORAI1 channels are constantly permeable for Ca 2+ , whereas the overactivity of the T184M ORAI1 channel is conditioned by the presence of STIM. Accordingly, and considering that the constant fluctuation of Ca 2+ levels within cellular compartments results in a varying sub-pool of activated STIM1/STIM2, and that STIM2 with is lower Ca 2+ affinity and higher lipid-binding avidity has been shown to be pre-recruited to the cortical ER at basal ER Ca 2+ concentrations [Parvez et al., 2008] , the endogenous STIM proteins in HEK-293T cells might be sufficient to partially activate the T184M ORAI1 channel. It is possible that the T184M mutation increases the binding sensitivity of the channel to STIM1 and STIM2 or to the transient receptor potential canonical (TRPC) channels to form a ternary complex with STIM1 at the PM [Lu et al., 2010] , which might explain the higher basal Ca 2+ level in cells expressing the T184M mutant even in the absence of store depletion. The extensive characterization of the T184M mutation might reveal a residue or domain regulating STIM-mediated channel gating. Excessive Ca 2+ entry was also reported for other ORAI1 mutations [Nesin et al., 2014; Endo et al., 2015] , but the STIMdependence of the channel activation was not investigated in these studies.
Further evidence for a different pathomechanism of the ORAI1 mutations comes from the co-expression experiments. HEK-293T or MEF-DKO cells co-expressing mCherry-STIM1 and any of the ORAI1-eGFP mutants induced excessive Ca 2+ influx following SOCE activation, but only G98S and V107M generated a continuous and long lasting Ca 2+ influx. In contrast, Ca 2+ influx significantly decreased over time in HEK-293T or MEF-DKO cells co-expressing STIM1 and T184M ORAI1. This discrepancy potentially reflects a difference in CDI of the mutant channels and/or their dissociation kinetics from STIM1. Alternatively, the higher basal Ca 2+ levels in cells expressing ORAI1 G98S or V107M might increase the threshold triggering CDI or Ca 2+ extrusion. It is also possible that the G98S and V107M mutations directly or indirectly impact on the Ca 2+ extrusion systems. In summary, our results suggest a mutation-specific pathomechanism. G98S and V107M induce constitutive channel opening independently of STIM, whereas T184M overactivation is conditioned by the presence of STIM. In accordance, the amino acid G98 resides in the hydrophobic gating hinge, and V107 locates near the Ca 2+ selectivity filter of the M1 transmembrane domain [Zhou et al., 2010; Hou et al., 2012] . Disturbance of these key functions is expected to impact on ion flow, which is confirmed by our functional data demonstrating constitutive Ca 2+ permeability independently of STIM. This conclusion is also sustained by similar findings based on the functional characterization of artificial M1 mutations [Zhang et al., 2011] . Conversely, T184 is not located in the channel pore, and the STIM-dependent overactivation of the mutant channel strongly suggests that transmembrane domain M3 is directly or indirectly implicated in STIM-mediated ORAI1 gating.
ORAI1 Mutations in M1 Induce a More Severe Phenotype
Considering the clinical presentation of our and all previously published patients with activating ORAI1 mutations [Nesin et al., 2014; Endo et al., 2015] , the most severe muscle phenotypes result from mutations in M1, a moderate muscle phenotype from a mutation in M2, and milder muscle phenotypes from mutations in M3 and M4. This correlates well with our functional data, demonstrating a stronger impact of M1 mutations on channel function.
Our patients were diagnosed with TAM based on biochemical blood tests and histological findings. All displayed repeatedly elevated serum CK levels in combination with prominent tubular aggregates as the major structural aberration on muscle biopsies. The clinical presentation was however variable, ranging from severe early-onset muscle weakness and contractures (patient 11200 from Family 1) to mild late-onset muscle weakness (patient 5510 from Family 3). A similar interfamilial variability was recently described for other families with ORAI1 mutations. G98S was described in two Japanese family presenting childhood-onset TAM, joint contractures, hypocalcaemia, rigid spine, and elevated CK levels [Endo et al., 2015] . We identified the same mutation in our unrelated Family 1, and the clinical manifestations were comparable. The same study reported a third Japanese family harboring the ORAI1 L138F mutation, and presenting with weaker clinical features involving adolescence-onset TAM, minor joint contractures, and slightly elevated CK levels. In addition, a family carrying the ORAI1 P245L mutation was described with late-onset TAM and increased CK levels [Nesin et al., 2014] .
Taking into account the clinical manifestation of all TAM patients with ORAI1 mutation, our functional data, and the published ORAI1 protein structure, we conclude that mutations affecting the pore lead to constitutive channel permeability, and result in early-onset muscle weakness often associated with contractures. In contrast, mutations affecting the concentric channel rings involve a STIM-dependent overactivity of ORAI1, and result in less severe symptoms with minor muscle weakness.
ORAI1 Patients Present Discrete Signs of Stormorken Syndrome
TAM in combination with miosis, thrombocytopenia, asplenia, ichthyosis, dyslexia/intellectual disability, and short stature defines Stormorken syndrome. Both TAM and Stormorken syndrome are caused by gain-of-function mutations in STIM1 and ORAI1 [Bohm et al., 2013; Misceo et al., 2014; Morin et al., 2014; Nesin et al., 2014; Endo et al., 2015] . To explore the possibilities that TAM and Stormorken syndrome are either different nosological entities or spectra of the same disease, we examined our patients for non-muscle phenotypes and reviewed the published ORAI1 cases. We noticed miosis (patient 11200, Family 1, and [Nesin et al., 2014] ), frequent episodes of bleeding (patient 11200, Family 1), ichthyosis, (patient 11200, Family 1), and dyslexia/intellectual disability (patients IV.1, and IV.2, Family 2, Family A [Endo et al., 2015] ]. These data show that signs of Stormorken syndrome are found in many patients with activating ORAI1 mutations, and we conclude that TAM and Stormorken syndrome are spectra of the same disease. This is of high importance for genetic diagnosis and counseling, as ORAI1 mutations should be considered in patients with elevated CK levels and prominent tubular aggregates on muscle biopsies, especially if they present signs of Stormorken syndrome.
Overactive SOCE Versus Underactive SOCE in Mendelian Disorders
STIM1 and ORAI1 act within the same SOCE pathway regulating Ca 2+ homeostasis in various tissues. The identification of gain-of-function mutations in STIM1 and ORAI1 represents a strong proof for the implication of aberrant SOCE in the development of TAM/Stormorken syndrome. This is sustained by our functional and immunolocalization studies demonstrating a pathomechanistic link between both proteins.
While heterozygous gain-of-function mutations in STIM1 or ORAI1 generate excessive Ca 2+ influx and result in the development of TAM/Stormorken syndrome [Bohm et al., 2013; Bohm et al., 2014; Hedberg et al., 2014; Misceo et al., 2014; Morin et al., 2014; Nesin et al., 2014; Endo et al., 2015; Markello et al., 2015] , homozygous loss-of-function mutations in either of the genes suppress Ca 2+ influx and are associated with severe immunodeficiency [Feske et al., 2006; McCarl et al., 2009; Picard et al., 2009; Byun et al., 2010; Fuchs et al., 2012; Lacruz and Feske 2015] (MIM# 612782, # 612783). We conclude that strict regulation of Ca 2+ homeostasis ensures normal physiology of muscle, leucocytes, platelets, skin, and other cells and tissues, and that overactive SOCE causes TAM/Stormorken syndrome, whereas underactive SOCE causes immunodeficiency.
Conclusions
Our work indicates for the first time a mutation-specific pathomechanism for ORAI1 gain-of-function mutations, thereby uncovers a clear genotype-phenotype correlation, and improves the understanding of the pathology of TAM/Stormorken syndrome and SOCE, altered in rare and common diseases.
